Immunological role and prognostic potential of CLEC10A in pan-cancer

Yan Qin; Lulu Wang; Lihua Zhang; Jiasheng Li; Lixian Liao; Lihaoyun Huang; Wei Li; Jianrong Yang

Immunological role and prognostic potential of CLEC10A in pan-cancer

Am J Transl Res. 2022 May 15;14(5):2844-2860. eCollection 2022.

Authors

Yan Qin^{1

2}, Lulu Wang^{1

2}, Lihua Zhang³, Jiasheng Li³, Lixian Liao³, Lihaoyun Huang³, Wei Li^{1

2}, Jianrong Yang^{1

2}

Affiliations

¹ Department of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region Nanning 530021, Guangxi, China.
² Research Center of Health Management, Guangxi Academy of Medical Sciences Nanning 530021, Guangxi, China.
³ Guangxi Medical University Cancer Hospital Nanning 530021, Guangxi, China.

PMID: 35702069
PMCID: PMC9185031

Abstract

Objectives: CLEC10A is expressed in a variety of cells, involved in a variety of biological pathways including immune response, and is closely related to the development of tumor immune response. However, the role of CLEC10A from a pan-cancer perspective has not yet been analyzed, and its role in human cancer prognosis and immunology remains largely unclear.

Methods: We studied the expression levels of CLEC10A and investigated its prognostic value in various cancers across distinct datasets including Oncomine, cBioPortal, and TCGA, and conducted immunohistochemical experiments using fresh bladder cancer and breast cancer samples to verify the results. In addition, we also performed GSEA of CLEC10A and explored the relationship between CLEC10A expression and immune infiltration, immune checkpoints, immune activation genes, immunosuppressive genes, chemokines and chemokine receptors.

Results: The results showed that the expression level of CLEC10A in most tumors was significantly lower compared with non-cancerous tissue, and the decreased expression was related to poor prognosis and more advanced cancer stages. We also found that the expression of CLEC10A was significantly related to the immunomodulatory interaction between lymph and non-lymphocytes. Furthermore, the expression of CLEC10A was not only significantly correlated with the level of infiltration of CD4+T cells and CD8+T cells, but also closely related to immune checkpoints, immune activation genes, immunosuppressive genes, chemokines, and chemokine receptors. Importantly, our analysis of the relationship between CLEC10A and TMB and MSI also confirmed the speculation that CLEC10A may influence antitumor immunity by regulating the composition and immune mechanisms of the tumor microenvironment.

Conclusions: In conclusion, CLEC10A may serve as a new target for tumor immunotherapy and has great potential as a molecular biomarker for predicting pan-cancer prognosis and immune infiltration.

Keywords: CLEC10A; immune checkpoint inhibitors; pan-cancer; prognosis; tumor immunity; tumor microenvironment.